On May 25, 2017 Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, reported the presentation of a poster describing the Phase 1 trial of CA-170, an oral small molecule dual inhibitor of immune checkpoints PD-1 and VISTA, in the treatment of patients with advanced solid tumors or lymphomas at the 2017 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting (Press release, Curis, MAY 25, 2017, View Source [SID1234519291]). The meeting will take place from June 2-6 in Chicago. Schedule your 30 min Free 1stOncology Demo! In addition, researchers from the Dana-Farber Cancer Institute and Boston Children’s Hospital will be presenting information on an investigator-initiated Phase 1 multicenter trial using CUDC-907, Curis’ proprietary drug candidate, to treat children and young adults with relapsed or refractory solid tumors, CNS tumors and lymphoma.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Additional information on the presentations can be found below and can be accessed at www.am.asco.org.
CA-170 Poster Presentation:
Date/Time: Monday, June 5, 8 AM — 11:30 AM CDT
Abstract Number: TPS3099
Presentation Title: Phase 1 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints PD-1 and VISTA, in patients (pts) with advanced solid tumor or lymphomas
CUDC-907 Poster Presentation:
Date/Time: Sunday, June 4, 8 AM — 11:30 AM CDT
Abstract Number: TPS10576
Presentation Title: Phase 1 multicenter trial of CUDC-907 in children and young adults with relapsed or refractory solid tumors, CNS tumors, and lymphoma